Saturday, December 9, 2023
-Advertisement-
2023 Data Protection Report
2023 Data Protection Report
2023 Data Protection Report
2023 Data Protection Report
-Advertisement-
2023 Data Protection Report
2023 Data Protection Report
2023 Data Protection Report
2023 Data Protection Report
HomeNewseHealthZeiss Medical Tech launches Intrabeam 600 to test breast cancer

Zeiss Medical Tech launches Intrabeam 600 to test breast cancer

Zeiss has installed more than 350 Intrabeam devices across the world and the first one in India is now available at the Fortis Cancer Institute, Bengaluru.

Follow Tech Observer on Google News

Zeiss has installed more than 350 Intrabeam devices across the world and the first one in India is now available at the Fortis Cancer Institute, Bengaluru.

Google News

Global health tech leader in ophthalmology and microsurgery, Medical Technology has announced to launch of a new device to treat breast cancer in India. According to the company, its new device Intrabeam 600 would provide Intraoperative Radiation Therapy (IORT) in India.

“The device offers the least disruptive treatment method available to patients diagnosed with early-stage breast cancer,” the company said.

So far, Zeiss has installed more than 350 Intrabeam devices across the world and the first one in India is now available at the Fortis Cancer Institute, .

“The Intrabeam 600 device is a major breakthrough in the treatment of early-stage breast cancer in women. But that's not all. Zeiss Medical Technology is committed to working for the advancement of microsurgery, promoting research and innovation to democratize and ease the treatment of fatal diseases like cancer,” ZEISS Medical Technology Strategic Business Unit Head Microsurgery Amarjeet Singh Tak said in a statement.

The IORT procedure available through Intrabeam 600 takes around 45 minutes to complete one session during the surgery. A single dose of intraoperative radiotherapy given after the removal of the tumor has significantly better outcomes as compared to whole breast radiotherapy, the company stated.

The company is also investing 10 million Euros annually in CARIn (Center for Advance Research in India) as it launches the IORT Innovation Lab to boost cancer research in India.

The IORT lab will be the center of innovation and experimentation to develop solutions to make IORT technology more affordable and provide better outcomes to patients.

CARIn, currently has 170 software and automation engineers, data scientists, clinical and quality specialists who are working on innovative solutions to advance microsurgery.

“Our investment in CARIn and the launch of IORT Lab is a big step towards boosting our research and innovation capabilities here in India,” Tak noted.

Get the day's headlines from Tech Observer straight in your inbox

- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here
Captcha verification failed!
CAPTCHA user score failed. Please contact us!
- Advertisement -2023 Data Protection Report
- Advertisement -ESDS SAP Hana

Subscribe to our Newsletter

83000+ Industry Leaders read it everyday

By subscribing you agree to our Privacy Policy, T&C and consent to receive newsletters and other important communications.
- Advertisement -

Thales completes $3.6 billion Imperva buyout, expands cybersecurity capabilities

This acquisition of Imperva, announced on July 25 and finalised earlier than the initially projected timeline of early 2024, marks a significant expansion of Thales' cybersecurity capabilities globally.

RELATED ARTICLES

- Advertisement -